First, the favorable preclinical data for ASP5094 that supported clinical investigation was obtained using a mouse model of acute arthritis in which administration of anti-mouse α9 antibody suppressed type II collagen-induced arthritis in both prophylactic and therapeutic regimens [37]. This evidence concerns the gene IGKV1D-22 and Arthritis.